Postoperative Donor Liver Damage Can Predict Recipient Short-Term Survival in Living Donor Liver Transplantation.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 18 12 2021
accepted: 29 12 2021
pubmed: 14 2 2022
medline: 1 4 2022
entrez: 13 2 2022
Statut: ppublish

Résumé

In living donor liver transplantation, surgical damage is a risk for graft dysfunction. We hypothesized that postoperative donor laboratory data reflect both donor liver damage and graft damage. Therefore, we evaluated how donor surgical factors affected recipient graft function and prognosis. From March 2002 to December 2020, 130 consecutive recipients and donors who underwent adult-to-adult living donor liver transplantation were analyzed. Donor perioperative surgical factors were evaluated to assess risk factors for recipient 90-day mortality by univariate analysis. Donor postoperative maximum levels of aspartate aminotransferase (AST; P = .016), alanine transaminase (P = .048), and prothrombin time-international normalized ratio (P = .034) were risk factors. Receiver operating characteristic analysis identified 214 U/L as the most appropriate cutoff value of donor postoperative AST. After excluding 22 pairs of patients without donor data, the 108 pairs were divided into 2 groups based on donor maximum AST (D-mAST) level: the low D-mAST group (D-mAST < 241 U/L, n = 39) and the high D-mAST group (D-mAST ≥ 241 U/L, n = 69). Donor age was significantly higher in recipients in the high D-mAST group than in the low D-mAST group (P = .033). Postoperative recipient maximum AST and alanine transaminase levels and 90-day mortality were significantly higher in the high D-mAST group than in the low D-mAST group (P = .001, P = .006, and P = .009, respectively). There were no significant differences in long-term survival, although 5-year survival was slightly lower in the high D-mAST group. Surgical liver damage to grafts, as assessed by postoperative donor AST levels, affected recipient short-term survival.

Sections du résumé

BACKGROUND BACKGROUND
In living donor liver transplantation, surgical damage is a risk for graft dysfunction. We hypothesized that postoperative donor laboratory data reflect both donor liver damage and graft damage. Therefore, we evaluated how donor surgical factors affected recipient graft function and prognosis.
PATIENTS AND METHODS METHODS
From March 2002 to December 2020, 130 consecutive recipients and donors who underwent adult-to-adult living donor liver transplantation were analyzed. Donor perioperative surgical factors were evaluated to assess risk factors for recipient 90-day mortality by univariate analysis.
RESULTS RESULTS
Donor postoperative maximum levels of aspartate aminotransferase (AST; P = .016), alanine transaminase (P = .048), and prothrombin time-international normalized ratio (P = .034) were risk factors. Receiver operating characteristic analysis identified 214 U/L as the most appropriate cutoff value of donor postoperative AST. After excluding 22 pairs of patients without donor data, the 108 pairs were divided into 2 groups based on donor maximum AST (D-mAST) level: the low D-mAST group (D-mAST < 241 U/L, n = 39) and the high D-mAST group (D-mAST ≥ 241 U/L, n = 69). Donor age was significantly higher in recipients in the high D-mAST group than in the low D-mAST group (P = .033). Postoperative recipient maximum AST and alanine transaminase levels and 90-day mortality were significantly higher in the high D-mAST group than in the low D-mAST group (P = .001, P = .006, and P = .009, respectively). There were no significant differences in long-term survival, although 5-year survival was slightly lower in the high D-mAST group.
CONCLUSIONS CONCLUSIONS
Surgical liver damage to grafts, as assessed by postoperative donor AST levels, affected recipient short-term survival.

Identifiants

pubmed: 35151495
pii: S0041-1345(22)00002-1
doi: 10.1016/j.transproceed.2021.12.040
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

418-423

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Akihiro Tanemura (A)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan. Electronic address: taneamail0827@gmail.com.

Koki Maeda (K)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Toru Shinkai (T)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Takahiro Ito (T)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Aoi Hayasaki (A)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Kazuyuki Gyoten (K)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Takehiro Fujii (T)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Yusuke Iizawa (Y)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Yasuhiro Murata (Y)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Naohisa Kuriyama (N)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Masashi Kishiwada (M)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Hiroyuki Sakurai (H)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Shugo Mizuno (S)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH